Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Eric Benevich Sells 19,818 Shares of Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Eric Benevich sold 19,818 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the sale, the insider now owns 40,778 shares in the company, valued at $5,438,154.08. The sale was disclosed in a filing with the SEC, which is available at this link.

Eric Benevich also recently made the following trade(s):

• On Thursday, March 14th, Eric Benevich sold 75,000 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $139.38, for a total value of $10,453,500.00.

Neurocrine Biosciences Stock Up 0.2 %

Shares of NBIX stock opened at $133.23 on Thursday. The firm has a market cap of $13.26 billion, a price-to-earnings ratio of 55.05 and a beta of 0.25. Neurocrine Biosciences, Inc. has a 52-week low of $89.04 and a 52-week high of $148.37. The company’s 50 day moving average is $136.19 and its 200 day moving average is $126.81.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Wednesday, February 7th. The company reported $1.44 EPS for the quarter, topping the consensus estimate of $1.13 by $0.31. The firm had revenue of $515.20 million during the quarter, compared to analyst estimates of $518.52 million. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The business’s revenue for the quarter was up 25.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.88 EPS. Analysts anticipate that Neurocrine Biosciences, Inc. will post 4.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Rice Hall James & Associates LLC grew its holdings in Neurocrine Biosciences by 195.5% in the first quarter. Rice Hall James & Associates LLC now owns 206,755 shares of the company’s stock worth $19,383,000 after purchasing an additional 136,782 shares during the last quarter. HighTower Advisors LLC increased its position in Neurocrine Biosciences by 48.8% during the 1st quarter. HighTower Advisors LLC now owns 5,745 shares of the company’s stock valued at $544,000 after buying an additional 1,883 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Neurocrine Biosciences by 27.7% in the first quarter. PNC Financial Services Group Inc. now owns 3,150 shares of the company’s stock valued at $296,000 after buying an additional 684 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in Neurocrine Biosciences in the first quarter valued at about $27,000. Finally, Dimensional Fund Advisors LP grew its stake in shares of Neurocrine Biosciences by 39.1% during the first quarter. Dimensional Fund Advisors LP now owns 417,604 shares of the company’s stock worth $39,148,000 after acquiring an additional 117,422 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on NBIX shares. StockNews.com upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, April 10th. Mizuho increased their target price on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the company a “neutral” rating in a research note on Thursday, February 8th. JPMorgan Chase & Co. raised their target price on shares of Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a report on Wednesday, March 20th. Finally, The Goldman Sachs Group upped their price target on shares of Neurocrine Biosciences from $134.00 to $153.00 and gave the company a “buy” rating in a report on Thursday, January 25th. Six equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $139.67.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.